Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Von Seggern ChristopherOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Aulin SherryOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Kenney Christopher JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Empfield James R.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:65,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Robin SherringtonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:65,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:DiFabio AndreaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Mortimer IanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:250,000Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Garofalo Elizabeth A.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,500Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Garofalo Elizabeth A.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,092Price:$45.69
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Garofalo Elizabeth A.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,408Price:$46.16
Filings by filing date
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Von Seggern ChristopherOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Aulin SherryOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Kenney Christopher JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Empfield James R.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:65,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Robin SherringtonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:65,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:DiFabio AndreaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Mortimer IanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:250,000Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Garofalo Elizabeth A.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,500Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Garofalo Elizabeth A.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,092Price:$45.69
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Garofalo Elizabeth A.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,408Price:$46.16
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3650 Gilmore Way VANCOUVER BC V5G 4W8 |
Tel: | N/A |
Website: | https://www.xenon-pharma.com |
IR: | See website |
Key People | ||
Ian C. Mortimer President, Chief Executive Officer, Director | Sherry Aulin Chief Financial Officer | James R. Empfield Executive Vice President - Drug Discovery |
Robin Paul Sherrington Executive Vice President - Strategy and Innovation | Christopher Kenney Chief Medical Officer | Christopher E. Von Seggern Chief Commercial Officer | Andrea Marie Difabio Chief Legal Officer, Corporate Secretary |
Business Overview |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company's product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS). |
Financial Overview |
For the fiscal year ended 31 December 2023, Xenon Pharmaceuticals Inc revenues decreased from $9.4M to $0K. Net loss applicable to common stockholders increased 46% to $182.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 58% to $154.4M (expense). |
Employees: | 251 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,492M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$210.51M as of Dec 31, 2023 |
Net annual income (TTM): | -$182.39M as of Dec 31, 2023 |
Free cash flow (TTM): | -$150.94M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 75,432,482 as of Feb 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |